Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a gout drug help heal brain bleeds?

NCT ID NCT07701512

Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This trial tests whether febuxostat, a drug typically used for gout, can improve recovery in people with a brain bleed (intracranial hemorrhage) who are treated without surgery. Participants take febuxostat or standard care for three months. The study measures consciousness levels and blood markers of inflammation to see if the drug helps reduce brain injury.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
febuxostat, a drug that lowers uric acid and may reduce inflammation
What this could lead to
If it works, this could point toward a simple, low-cost drug to help people recover from a brain bleed without needing surgery.
What could go wrong
This is a small, early-phase trial with only 46 participants, so results may not apply broadly. Febuxostat is not proven for this use and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 46 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Age ≥ 18 years old. * Diagnosed with intracranial hemorrhage confirmed by CT scan. * Managed conservatively regarding clinical guidelines. * Able to provide informed consent or have a legal representative provide consent. Exclusion Criteria: * • Patients with a history of previous brain surgery or significant neurological disorders. * Severe comorbidities (e.g., uncontrolled diabetes, severe cardiac disease). * Allergy or contraindication to febuxostat. * Pregnant or breastfeeding women. * Patients requiring surgical intervention for hematoma evacuation. * Renal impairment with SCr \> 4 * Liver impairment with INR \> 5 * Significant deterioration ( GCS \< 8 )

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intracranial hemorrhage are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intracerebral hemorrhage Intracranial Hemorrhages

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intracranial hemorrhage

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Neurosurgery department Mansoura university hospitals

    RECRUITING

    Al Mansurah, Dakahlia Governorate, 35511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.